JPRN-jRCT2021220013招募中2 期
A Phase 2/3, Multicenter, Randomized, Double-Blind Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Oral Ozanimod (RPC1063) in Pediatric Subjects with Moderately to Severely Active Ulcerative Colitis with an Inadequate Response to Conventional Therapy
iu W. Jerry0 个研究点目标入组 120 人开始时间: 2022年6月18日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 120
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 2age old 至 <= 17age old（—）
- 性别
- All
入选标准
- •Moderately to severely active Ulcerative Colitis (UC) diagnosed prior to the Screening Visit
- •- Evidence of UC extending beyond the rectum, as determined by baseline endoscopy
- •- Has had an inadequate response, loss of response to, or is intolerant to at least 1 of the following treatments for UC: oral aminosalicylates, systemic corticosteroids, immunomodulators, biologic therapy
排除标准
- •- Diagnosis of Crohn's disease or indeterminate colitis
- •- Has documentation of positive test for toxin producing Clostridium difficile, or polymerase chain reaction examination of the stool
- •- Apheresis within 2 weeks of randomization
- •- History of or currently active primary or secondary immunodeficiency, or participants with known genetic disorders as a cause for colitis
研究者
相似试验
进行中（未招募）
1 期
Study to Evaluate the Efficacy and Safety of AK002 in Subjects with Active Eosinophilic EsophagitisActive Eosinophilic Esophagitis (EoE)MedDRA version: 20.1Level: PTClassification code 10064212Term: Eosinophilic oesophagitisSystem Organ Class: 10017947 - Gastrointestinal disordersEUCTR2019-004391-19-NLAllakos Inc.300
已完成
2 期
A Phase 2/3, Multicenter, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of AK002 in Adult and Adolescent Subjects with Active Eosinophilic Esophagitisactive Eosinophilic Esophagitis (EoE)10018012NL-OMON55008Allakos Inc.10
进行中（未招募）
1 期
An Efficacy and Safety Study of MYOBLOC® in the Treatment of Adults withincreased muscle tone in a lower extremity or extremities leading to difficulties of movement and walking and followed by an Open-Label Multiple-Treatment Safety Studyower Limb SpasticityMedDRA version: 20.0Level: LLTClassification code 10041416Term: SpasticitySystem Organ Class: 100000004852EUCTR2019-003647-29-PLSolstice Neurosciences, LLC, a subsidiary of MDD US Operations, LLC272
招募中
2 期
Clinical Trial to Evaluate the Efficacy and Safety of Tablets of Purified Aqueous Extract of Cocculus hirsutus in Treatment of Mild COVID-19 DiseaseCTRI/2021/09/036786Sun Pharmaceutical Industries Limited
进行中（未招募）
1 期
An Efficacy and Safety Study of MYOBLOC® in the Treatment of Adults with increased muscle tone in a lower extremity or extremities leading to difficulties of movement and walking and followed by an Open-Label Multiple-Treatment Safety Studyower Limb SpasticityMedDRA version: 20.0Level: LLTClassification code 10041416Term: SpasticitySystem Organ Class: 100000004852EUCTR2019-003647-29-HUSolstice Neurosciences a wholly-owned subsidiary of US WorldMeds, LLC272